Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Opus Genetics (IRD)
NASDAQ:IRD
Holding IRD?
Track your performance easily
IRD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.07 - $3.40
Previous Close$1.35
Volume88.51K
Average Volume (3M)141.07K
Market Cap
$36.78M
Enterprise Value-$4.63M
Total Cash (Recent Filing)$41.41M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Nov 08, 2024EPS Estimate
-$0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding26,198,444
10 Day Avg. Volume195,491
30 Day Avg. Volume141,075
Standard Deviation0.20
R-Squared0.00269
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.87
Price to Sales (P/S)1.86
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.28
Enterprise Value/Gross Profit-0.24
Enterprise Value/Ebitda0.33
Forecast
1Y Price Target
$13.00Price Target Upside877.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Commercialization OpportunitiesFDA-approval and launch of phentolamine (ophthalmic solution 0.75%) Ryzumvi reflects the beginning of commercial efforts from the established development and commercialization global license agreement with partner Viatris Inc.
Gene Therapy Market PotentialGene therapy for rare diseases faces limited competition and may charge up to $850k per patient, similar to LUXTURNA.
Ryzumvi Development And Financial StrategyOcuphire will manage the trials with partner Viatris, who will reimburse Ocuphire for agreed-to budgeted costs related to Ryzumvi development through FDA approval.
Bears Say
Clinical TrialsDelays or unfavorable outcomes from Ocuphire's clinical trials could adversely affect the company's valuation.
Regulatory UpdatesNegative market sentiment is heightened due to delayed regulatory updates for APX3330 and a missed target for Ryzumvi.
Research And DevelopmentHigher study costs and longer trial time for APX3330 could negatively impact financial stability.
---
Ownership Overview
6.21% Insiders
4.44% Mutual Funds
0.82% Other Institutional Investors
85.14% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IRD FAQ
What was Opus Genetics’s price range in the past 12 months?
Opus Genetics lowest stock price was $1.07 and its highest was $3.40 in the past 12 months.
What is Opus Genetics’s market cap?
Currently, no data Available
When is Opus Genetics’s upcoming earnings report date?
Opus Genetics’s upcoming earnings report date is Nov 08, 2024 which is in 8 days.
How were Opus Genetics’s earnings last quarter?
Opus Genetics released its earnings results on Aug 13, 2024. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.255 by -$0.045.
Is Opus Genetics overvalued?
According to Wall Street analysts Opus Genetics’s price is currently Undervalued.
Does Opus Genetics pay dividends?
Opus Genetics does not currently pay dividends.
What is Opus Genetics’s EPS estimate?
Opus Genetics’s EPS estimate is -$0.25.
How many shares outstanding does Opus Genetics have?
Opus Genetics has 31,435,507 shares outstanding.
What happened to Opus Genetics’s price movement after its last earnings report?
Opus Genetics reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.255. Following the earnings report the stock price went down -21.084%.
Which hedge fund is a major shareholder of Opus Genetics?
Currently, no hedge funds are holding shares in IRD
---
Opus Genetics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (877.44% Upside)
$13.00 (877.44% Upside)
Blogger Sentiment
Bullish
IRD Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 7.8%
Last 30 Days ▼ 9.0%
Last 30 Days ▼ 9.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.08%
12-Months-Change
Fundamentals
Return on Equity
-36.01%
Trailing 12-Months
Asset Growth
3.15%
Trailing 12-Months
Company Description
Opus Genetics
Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.
---
IRD Stock 12 Month Forecast
Average Price Target
$13.00
▲(877.44% Upside)
Technical Analysis
Best Analysts Covering IRD
1 Year
1 Year Success Rate
6/18 ratings generated profit
1 Year Average Return
-2.84%
reiterated a buy rating 3 months ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -2.84% per trade.
---